Myleofibrosis medical therapy

Revision as of 15:27, 21 September 2012 by Kalsang Dolma (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Myleofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myleofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myleofibrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myleofibrosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myleofibrosis medical therapy

on Myleofibrosis medical therapy

Myleofibrosis medical therapy in the news

Blogs on Myleofibrosis medical therapy

Directions to Hospitals Treating Myleofibrosis

Risk calculators and risk factors for Myleofibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Myleofibrosis has no known cure. Lenalidomide (brand name Revlimid) and Thalidomide are drugs that can be used in its treatment, though they can cause gout and leave the patient susceptible to diseases such as pneumonia. Frequent blood transfusions may also be required.

References

Template:WH Template:WS